SUPPLEMENTARY INFORMATION |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SUPPLEMENTARY INFORMATION | SUPPLEMENTARY INFORMATION
1.In 2025, interest income includes non-cash interest income related to the $350 million Derby related party notes receivable. In 2026, interest income includes non-cash interest income related to both the $350 million Derby and the $300 million Aramids related party notes receivable. Refer to Note 10 for further details. 2.The three and nine months ended September 30, 2025 include the non-cash mark-to-market loss and gain, respectively, related to the 2022 Swaps (as defined below) and 2024 Swaps (as defined below), offset by the interest settlement loss on the 2022 Swaps. Refer to Note 17 for further details. 3.Refer to Note 18 for further details. Cash, Cash Equivalents and Restricted Cash "Cash, cash equivalents and restricted cash at end of period" in the interim Consolidated Statements of Cash Flows includes the following: At September 30, 2026 and December 31, 2025, the Company had "Cash and cash equivalents" in the interim Condensed Consolidated Balance Sheets of $1,652 million and $715 million, respectively. At September 30, 2026 and December 31, 2025, the Company had "Restricted cash and cash equivalents" in the interim Condensed Consolidated Balance Sheets of $7 million and $42 million, respectively, of which $3 million and $37 million, respectively, is attributable to the MOU cost sharing arrangement. Additional information can be found in Note 13. Within discontinued operations related to the Aramids Divestiture, the Company had $3 million within "Cash and cash equivalents" at December 31, 2025. Refer to Note 3 for further details. Accrued and Other Current Liabilities "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets were $953 million at September 30, 2026 and $882 million at December 31, 2025. Accrued payroll, which is a component of "Accrued and other current liabilities", was $218 million at September 30, 2026 and $238 million at December 31, 2025. At September 30, 2026 and December 31, 2025, the balance includes approximately $369 million and $323 million related to accrued indemnified current liabilities associated with the Electronics Separation, MOU and environmental obligations and the Aramids Divestiture further discussed in Note 3 and Note 13. "Accrued and other current liabilities" also includes amounts accrued for certain litigation matters. No other component of "Accrued and other current liabilities" was more than five percent of total current liabilities at September 30, 2026 and December 31, 2025. Leases The Company has leases in which it is the lessor, with the largest being a result of the Electronics Separation and the divestiture in 2021 of the Nutrition & Biosciences business to International Flavor & Fragrance Inc. ("IFF") in a Reverse Morris Trust transaction (the "N&B Transaction"). In connection with the Electronics Separation, N&B Transaction and divestiture in 2022 of the majority of the businesses comprising the historical Materials & Mobility segment to Celanese Corporation ("Celanese"), and the Aramids Divestiture to Arclin in 2026, DuPont entered into leasing arrangements with Qnity, IFF, Celanese and Arclin, whereby DuPont is leasing certain properties, including office spaces and R&D laboratories. These leases are classified as operating leases. Lease agreements where the Company is the lessor have final expirations through 2041. For the three months ended September 30, 2026 and 2025, total lease income was $29 million and $17 million, respectively, for which the net profits recognized from these leases were approximately $10 million and $5 million, respectively. For the nine months ended September 30, 2026 and 2025, total lease income was $86 million and $51 million, respectively, for which the net profits recognized from these leases were approximately $29 million and $14 million, respectively. Total lease income for each period presented is recorded in "" and "Research and development expenses". Contractual lease income for the remainder of 2026 through 2041 ranges from $1 million to $91 million annually.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||